Oxidative stress in chronic vascular disease: From prediction to prevention

Vascular Pharmacology

Volumn 74, Issue , 2015, Pages 23-37

  Santilli, Francesca ^a   D'Ardes, Damiano ^a   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

11 Dehydro TXB2 (PubChem CID: 5280891); Alpha Tocopherol (PubChem CID: 14985); Angiotensin II (PubChem CID: 172,198); Antioxidants; Ascorbic acid (PubChem CID: 54670067); Biomarkers; Diabetes; Hydroxide (PubChem CID: 961); Hypertension; Isoprostanes; NADP+ (PubChem CID: 5886); Nitric oxide (PubChem CID: 145068); Oxidative stress; Peroxynitrite (PubChem CID: 104806); Superoxide (PubChem CID: 5359597); Tetrahydrobiopterin (PubChem CID: 44257)

Indexed keywords

2 ACETYLPHENOTHIAZINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDEHYDE DEHYDROGENASE ISOENZYME 2; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GK 136901; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; METFORMIN; MICRORNA; OXIDOREDUCTASE INHIBITOR; PENTAERYTHRITYL TETRANITRATE; POLYPHENOL DERIVATIVE; PROTEIN KINASE C; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; VAS 2870; VAS 3947; VASCULAR TARGETING AGENT;

ALCOHOL CONSUMPTION; ATHEROGENESIS; ATHEROSCLEROSIS; CHRONIC DISEASE; CHRONIC VASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW (TOPIC); VASCULAR DISEASE; ANIMAL; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BIOMARKERS; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; VASCULAR DISEASES;

EID: 84947572299     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.09.003     Document Type: Review

References (195)

1. Li H., Horke S., Förstermann U. Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol. Sci. 2013, 34:313-319.
2. Rao F., Zhang K., Khandrika S., Mahata M., Fung M.M., Ziegler M.G., et al. Isoprostane, an "intermediate phenotype" for oxidative stress heritability, risk trait associations, and the influence of chromogranin B polymorphism. J. Am. Coll. Cardiol. 2010, 56:1338-1350.
3. Passaglia P., Ceron C.S., Mecawi A.S., Antunes-Rodrigues J., Coelho E.B., Tirapelli C.R. Angiotensin type 1 receptor mediates chronic ethanol consumption-induced hypertension and vascular oxidative stress. Vasc. Pharmacol. 2015, (pii:S1537-1891(15)00071-3).
4. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T.R., Horowitz J.C., et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 2009, 15:1077-1081.
5. Antoniades C., Shirodaria C., Crabtree M., Rinze R., Alp N., Cunnington C., et al. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007, 116:2851-2859.
6. Antoniades C., Bakogiannis C., Leeson P., Guzik T.J., Zhang M.H., Tousoulis D., et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011, 124. 335-5).
7. Cunnington C., Van Assche T., Shirodaria C., Kylintireas I., Lindsay A.C., Lee J.M., et al. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 2012, 125:1356-1366.
8. Shirodaria C., Antoniades C., Lee J., Jackson C.E., Robson M.D., Francis J.M., et al. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation 2007, 115:2262-2270.
9. Pignatelli P., Carnevale R., Cangemi R., Loffredo L., Sanguigni V., Stefanutti C., et al. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2010, 30:360-367.
10. Violi F., Pignatelli P. Clinical application of NOX activity and other oxidative biomarkers in cardiovascular disease: a critical review. Antioxid. Redox Signal. 2015, 23:514-532.
11. Niccoli G., Celestini A., Calvieri C., Cosentino N., Falcioni E., Carnevale R., et al. Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. Eur Heart J Acute Cardiovasc. Care 2013, 2:379-388.
12. Loffredo L., Martino F., Carnevale R., Pignatelli P., Catasca E., Perri L., et al. Obesity and hypercholesterolemia are associated with NOX2 generated oxidative stress and arterial dysfunction. J. Pediatr. 2012, 161:1004-1009.
13. Angelico F., Loffredo L., Pignatelli P., Augelletti T., Carnevale R., Pacella A., et al. Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Intern. Emerg. Med. 2012, 7:219-227.
14. Olza J., Aguilera C.M., Gil-Campos M., Leis R., Bueno G., Valle M., et al. Continuous metabolic syndrome score is associated with specific biomarkers of inflammation and CVD risk in prepubertal children. Ann. Nutr. Metab. 2015, 66:72-79.
15. Derosa G., D'Angelo A., Mugellini A., Pesce R.M., Fogari E., Maffioli P. Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. Curr. Med. Res. Opin. 2012, 28:1435-1445.
16. Tretjakovs P., Jurka A., Bormane I., Mikelsone I., Elksne K., Krievina G., et al. Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina. Clin. Chim. Acta 2012, 413:25-29.
17. Olza J., Aguilera C.M., Gil-Campos M., Leis R., Bueno G., Martínez-Jiménez M.D., et al. Myeloperoxidase is an early biomarker of inflammation and cardiovascular risk in prepubertal obese children. Diabetes Care 2012, 35:2373-2376.
18. Kataoka Y., Shao M., Wolski K., Uno K., Puri R., Murat Tuzcu E., et al. Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound. Atherosclerosis 2014, 232:377-383.
19. Sautin Y.Y., Johnson R.J. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008, 27:608-619.
20. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000, 283:2404-2410.
21. Berezin A.E., Kremzer A.A., Samura T.A., Berezina T.A., Martovitskaya Y.V. Serum uric acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients. J. Cardiovasc. Thorac. Res. 2014, 6(3):153-162.
22. Carr A.C., Zhu B.Z., Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ. Res. 2000, 87:349-354.
23. Nishi E.E., Campos R.R., Bergamaschi C.T., de Almeida V.R., Ribeiro D.A. Vitamin C prevents DNA damage induced by renovascular hypertension in multiple organs of Wistar rats. Hum. Exp. Toxicol. 2010, 29:593-599.
24. Botelho-Ono M.S., Pina H.V., Sousa K.H.F., Nunes F.C., Medeiros I.A., Braga V.A. Acute superoxide scavenging restores depressed baroreflex sensitivity in renovascular hypertensive rats. Auton. Neurosci. 2011, 159:38-44.
25. Bruno R.M., Daghini E., Ghiadoni L., Sudano I., Rugani I., Varanini M., et al. Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. Am. J. Clin. Nutr. 2012, 96:302-308.
26. Chelazzi C., Villa G., De Gaudio A.R. Postoperative atrial fibrillation. ISRN Cardiol. 2011, 203179. (2011).
27. May J.M., Harrison F.E. Role of vitamin C in the function of the vascular endothelium. Antioxid. Redox Signal. 2013, 19:2068-2083.
28. Ashor A.W., Siervo M., Lara J., Oggioni C., Afshar S., Mathers J.C. Effect of vitamin C and vitamin E supplementation on endothelial function: a systematic review and meta-analysis of randomised controlled trials. Br. J. Nutr. 2015, 113:1182-1194.
29. Montero D., Walther G., Stehouwer C.D., Houben A.J., Beckman J.A., Vinet A. Effect of antioxidant vitamin supplementation on endothelial function in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Obes. Rev. 2014, 15:107-116.
30. Traber M.G. Vitamin E inadequacy in humans: causes and consequences. Adv. Nutr. 2014, 5:503-514.
31. Bozaykut P., Karademir B., Yazgan B., Sozen E., Siow R.C., Mann G.E., et al. Effects of vitamin E on peroxisome proliferator-activated receptor γ and nuclear factor-erythroid 2-related factor 2 in hypercholesterolemia-induced atherosclerosis. Free Radic. Biol. Med. 2014, 70:174-181.
32. Gupta S., Sharma T.K., Kaushik G.G., Shekhawat V.P. Vitamin E supplementation may ameliorate oxidative stress in type 1 diabetes mellitus patients. Clin. Lab. 2011, 57:379-386.
33. Sesso H.D., Buring J.E., Christen W.G., Kurth T., Belanger C., MacFadyen J., et al. Vitamins E and C in the prevention of cardiovascular disease in men: the physicians' health study II randomized trial. JAMA 2008, 300:2123-2133.
34. Myung S.K., Ju W., Cho B., Oh S.W., Park S.M., Koo B.K., et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013, 346:f10.
35. Upston J.M., Terentis A.C., Stocker R. Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J. 1999, 13:977-994.
36. Niki E. Role of vitamin E as a lipid-soluble peroxyl radical scavenger: in vitro and in vivo evidence. Free Radic. Biol. Med. 2014, 66:3-12.
37. Aggarwal B.B., Sundaram C., Prasad S., Kannappan R. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem. Pharmacol. 2010, 80:1613-1631.
38. Ali S.F., Woodman O.L. Tocotrienol rich palm oil extract is more effective than pure tocotrienols at improving endothelium-dependent relaxation in the presence of oxidative stress. Oxidative Med. Cell. Longev. 2015, 150829. (2015).
39. Mueller C.F., Laude K., McNally J.S., Harrison D.G. ATVB in focus: redox mechanisms in blood vessels. Arterioscler. Thromb. Vasc. Biol. 2005, 25:274-278.
40. Blankenberg S., Rupprecht H.J., Bickel C., Torzewski M., Hafner G., Tiret L., et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N. Engl. J. Med. 2003, 349:1605-1613.
41. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 1998, 101:1581-1590.
42. Meagher E.A., FitzGerald G.A. Indices of lipid peroxidation in vivo: strenghts and limitations. Free Radic. Biol. Med. 2000, 28:1745-1750.
43. Pirinccioglu A.G., Gökalp D., Pirinccioglu M., Kizil G., Kizil M. Malondialdehyde (MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in subjects with familial hypercholesterolemia. Clin. Biochem. 2010, 43:1220-1224.
44. Viigimaa M., Abina J., Zemtsovskaya G., Tikhaze A., Konovalova G., Kumskova E., et al. Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis. Blood Press. 2010, 19:164-168.
45. Santilli F., Vazzana N., Bucciarelli L.G., Davì G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr. Med. Chem. 2009, 16:940-952.
46. Santilli F., Vazzana N., Liani R., Guagnano M.T., Davì G. Platelet activation in obesity and metabolic syndrome. Obes. Rev. 2012, 13:27-42.
47. Santilli F., Blardi P., Scapellato C., Bocchia M., Guazzi G., Terzuoli L., et al. Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with Familial Combined Hyperlipidemia and/or Metabolic syndrome. Vasc Pharm 2015, (pii:S1537-1891(15)00073-7).
48. Tesarova P., Cabinakova M., Mikulova V., Zima T., Kalousova M. RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?. Neoplasma 2015, 62:353-364.
49. Santilli F., Bucciarelli L., Noto D., Cefalù A.B., Davì V., Ferrante E., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 2007, 43:1255-1262.
50. Vazzana N., Guagnano M.T., Cuccurullo C., Ferrante E., Lattanzio S., Liani R., et al. Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. J. Clin. Endocrinol. Metab. 2012, 97:1726-1730.
51. Santilli F., Vazzana N., Iodice P., Lattanzio S., Liani R., Bellomo R.G., et al. Effects of high-amount-high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis. Thromb. Haemost. 2013, 110:1232-1240.
52. Hanssen N.M., Wouters K., Huijberts M.S., Gijbels M.J., Sluimer J.C., Scheijen J.L., et al. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur. Heart J. 2014, 35:1137-1146.
53. Davì G., Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 2005, 14:760-764.
54. Davì G., Falco A., Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem. Phys. Lipids 2004, 128:149-163.
55. Davies S.S., Roberts L.J. F-2 isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic. Biol. Med. 2011, 50:559-566.
56. Roberts L.J., Morrow J.D. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 2000, 28:505-513.
57. Davì G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999, 99:224-229.
58. Davì G., Chiarelli F., Santilli F., Pomilio M., Vigneri S., Falco A., et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003, 107:3199-3203.
59. Patrignani P., Panara M.R., Tacconelli S., Seta F., Bucciarelli T., Ciabattoni G., et al. Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 2000, 102:539-545.
60. Liani R., Halvorsen B., Sestili S., Handberg A., Santilli F., Vazzana N., et al. Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic. Biol. Med. 2012, 52:1318-1324.
61. Puccetti L., Santilli F., Pasqui A.L., Lattanzio S., Liani R., Ciani F., et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 2011, 214:122-128.
62. Dragani A., Falco A., Santilli F., Basili S., Rolandi G., Cerasa L., et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. Thromb. Haemost. 2012, 108:533-542.
63. Patrono C., Falco A., Davì G. Isoprostane formation and inhibition in atherothrombosis. Curr. Opin. Pharmacol. 2005, 5:198-203.
64. Guagnano M.T., Ferroni P., Santilli F., Paoletti V., Manigrasso M.R., Pescara L., et al. Determinants of platelet activation in hypertensives with microalbuminuria. Free Radic. Biol. Med. 2009, 46:922-927.
65. Keaney J.F., Larson M.G., Vasan R.S., Wilson P.W.F., Lipinska I., Corey D., et al. Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 2003, 23:434-439.
66. Pou K.M., Massaro J.M., Hoffmann U., Vasan R.S., Maurovich-Horvat P., Larson M.G., et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007, 116:1234-1241.
67. Santilli F., Davì G., Consoli A., Cipollone F., Mezzetti A., Falco A., et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2006, 47:391-397.
68. Davì G., Guagnano M.T., Ciabattoni G., Basili S., Falco A., Marinopiccoli M., et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002, 288:2008-2014.
69. Vazzana N., Santilli F., Sestili S., Cuccurullo C., Davì G. Determinants of increased cardiovascular disease in obesity and metabolic syndrome. Curr. Med. Chem. 2011, 18:5267-5280.
70. Meyer K.A., Sijtsma F.P., Nettleton J.A., Steffen L.M., Van Horn L., Shikany J.M., et al. Dietary patterns are associated with plasma F-isoprostanes in an observational cohort study of adults. Free Radic. Biol. Med. 2013, 57:201-209.
71. Davì G., Gresele P., Violi F., Basili S., Catalano M., Giammarresi C., et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997, 96:69-75.
72. Davì G., Rini G.B., Averna M., Novo S., Di Fede G., Pinto A., et al. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. Thromb. Res. 1982, 26:359-370.
73. LeLeiko R.M., Vaccari C.S., Sola S., Merchant N., Nagamia S.H., Thoenes M., et al. Usefulness of elevations in serum choline and free F2-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am. J. Cardiol. 2009, 104:638-643.
74. Roest M., Voorbij H.A., Van der Schouw Y.T., Peeters P.H., Teerlink T., Scheffer P.G. High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women. J. Clin. Lipidol. 2008, 2:298-303.
75. Pignatelli P., Pastori D., Carnevale R., Farcomeni A., Cangemi R., Nocella C., et al. Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. Thromb. Haemost. 2015, 113:617-624.
76. Patrono C., FitzGerald G.A. Isoprostane: potential markers of oxidant stress in atherothrombotic disease. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2309-2315.
77. Kuo H.C., Yen H.C., Huang C.C., Hsu W.C., Wei H.J. Lin CL. Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer's disease. Int J Neurosci 2014 Oct 29.
78. Asombang A.W., Kayamba V., Mwanza-Lisulo M., Colditz G., Mudenda V., Yarasheski K., et al. Gastric cancer in Zambian adults: a prospective case-control study that assessed dietary intake and antioxidant status by using urinary isoprostane excretion. Am. J. Clin. Nutr. 2013, 97:1029-1035.
79. Kong S.Y., Bostick R.M., Flanders W.D., McClellan W.M., Thyagarajan B., Gross M.D., et al. Oxidative balance score, colorectal adenoma, and markers of oxidative stress and inflammation. Cancer Epidemiol. Biomark. Prev. 2014, 23:545-554.
80. Santilli F., Mucci L., Davì G. TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. Intern. Emerg. Med. 2011, 6:203-212.
81. Undas A., Siudak Z., Topór-Madry R., Leśniak M., Tracz W. Simvastatin administration reduces thromboxane production in subjects taking aspirin: links between aspirin resistance and thrombin generation. Int. J. Cardiol. 2012, 154:59-64.
82. Santilli F., Davì G., Basili S., Lattanzio S., Cavoni A., Guizzardi G., et al. Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. J. Thromb. Haemost. 2010, 8:914-922.
83. Davì G., Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 2007, 357:2482-2494.
84. Bauer J., Ripperger A., Frantz S., Ergün S., Schwedhelm E., Benndorf R.A. Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation. Br. J. Pharmacol. 2014, 171:3115-3131.
85. Santilli F., Lapenna D., La Barba S., Davì G. Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. Free Radic. Biol. Med. 2015, 80:101-110.
86. Schwedhelm E., Bierend A., Maas R., Trinks R., Kom G.D., Tsikas D., et al. Redox-generated isoprostanes are associated with residual platelet activity in aspirin treated patients with stable coronary heart disease. J. Thromb. Haemost. 2010, 8:2662-2670.
87. Kranzhofer R., Ruef J. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX)1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism. Platelets 2006, 17:163-169.
88. Ames P.R., Batuca J.R., Muncy I.J., DeLaTorre I.G., Pascoe-Gonzales S., Guyer K., et al. Aspirinin sensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. Thromb. Res. 2012, 30:350-354.
89. Santilli F., Paloscia L., Liani R., Di Nicola M., Di Marco M., Lattanzio S., et al. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. J. Am. Heart Assoc. 2014, 3.
90. Pastori D., Pignatelli P., Carnevale R., Violi F. Nox-2 up-regulation and platelet activation: novel insights. Prostaglandins Other Lipid Mediat. 2015, (pii:S1098-8823(15)00040-4).
91. Cangemi R., Pignatelli P., Carnevale R., Nigro C., Proietti M., Angelico F., et al. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes 2012, 61:1626-1632.
92. Carnevale R., Loffredo L., Pignatelli P., Nocella C., Bartimoccia S., Di Santo S., et al. Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers. J. Thromb. Haemost. 2012, 10:125-132.
93. Nickenig G., Bäumer A.T., Temur Y., Kebben D., Jockenhövel F., Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131-2134.
94. Stepp D.W., Ou J., Ackerman A.W., Welak S., Klick D., Pritchard K.A. Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H750-H759.
95. Bergt C., Pennathur S., Fu X., Byun J., O'Brien K., McDonald T.O., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. 2004, 101:13032-13037.
96. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 2011, 364:127-135.
97. Ferroni P., Basili S., Paoletti V., Davì G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr. Metab. Cardiovasc. Dis. 2006, 16:222-233.
98. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111:1201-1209.
99. White C.R., Brock T.A., Chang L.Y., Crapo J., Briscoe P., Ku D., et al. Superoxide and peroxynitrite in atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1044-1048.
100. Korbecki J., Baranowska-Bosiacka I., Gutowska I., Chlubek D. The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid. J. Physiol. Pharmacol. 2013, 64:409-421.
101. Touyz R.M. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?. Hypertension 2004, 44:248-252.
102. Epstein B.J., Smith S.M., Choksi R. Recent changes in the landscape of combination RAS blockade. Expert. Rev. Cardiovasc. Ther. 2009, 7:1373-1384.
103. Touyz R.M. Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz. J. Med. Biol. Res. 2004, 37:1263-1273.
104. Touyz R.M., Schiffrin E.L. Signal transduction mechanisms mediating the physiological and patho-physiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev. 2000, 52:639-672.
105. Klatsky A.L., Friedmani G.D., Armstrong M.A. The relationships between alcoholic beverage use and other trials to blood pressure: a new Kaiser Permanente study. Circulation 1986, 73:628-636.
106. Lian C. L'alcolisme cause d'hipertension arterielle. Bull. Acad. Natl Med. 1915, 74:525-528.
107. Marchi K.C., Muniz J.J., Tirapelli C.R. Hypertension and chronic ethanol consumption: what do we know after a century of study?. World J. Cardiol. 2014, 6:283-294.
108. Toda N., Ayajiki K. Vascular actions of nitric oxide as affected by exposure to alcohol. Alcohol 2010, 45:347-355.
109. Ceron C.S., Marchi K.C., Muniz J.J., Tirapelli C.R. Vascular oxidative stress: a key factor in the development of hypertension associated with ethanol consumption. Curr. Hypertens. Rev. 2014, 10:213-222.
110. Shirpoor A., Salami S., Khadem Ansari M.H., Ilkhanizadeh B., Abdollahzadeh N. Ethanol promotes rat aortic vascular smooth muscle cell proliferation via increase of homocysteine and oxidized-low-density lipoprotein. J. Cardiol. 2013, 62:374-378.
111. Gonzaga N.A., Mecawi A.S., Antunes-Rodrigues J., De Martinis B.S., Padovan C.M., Tirapelli C.R. Ethanol withdrawal increases oxidative stress and reduces nitric oxide bioavailability in the vasculature of rats. Alcohol 2015, 49:47-56.
112. Husain K., Ferder L., Ansari R.A., Lalla J. Chronic ethanol ingestion induces aortic inflammation/oxidative endothelial injury and hypertension in rats. Hum. Exp. Toxicol. 2011, 30:930-939.
113. Tirapelli C.R., Leone A.F., Yogi A., Tostes R.C., Lanchote V.L., Uyemura S.A., et al. Ethanol consumption increases blood pressure and alters the responsiveness of the mesenteric vasculature in rats. J. Pharm. Pharmacol. 2008, 60:331-341.
114. Crestani C.C., Lopes da Silva A., Scopinho A.A., Ruginsk S.G., Uchoa E.T., Correa F.M., et al. Cardiovascular alterations at different stages of hypertension development during ethanol consumption: time-course of vascular and autonomic changes. Toxicol. Appl. Pharmacol. 2014, 280:245-255.
115. Husain K., Vazquez M., Ansari R.A., Malafa M.P., Lalla J. Chronic alcohol-induced oxidative endothelial injury relates to angiotensin II levels in the rat. Mol. Cell. Biochem. 2008, 307:51-58.
116. 1 and AT pathways in aortic responses to angiotensin II after stress and ethanol consumption in rats. Stress 2014, 17:512-519.
117. Aouacheri O., Saka S., Krim M., Messaadia A., Maidi I. The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus. Can. J. Diabetes 2015, 39:44-49.
118. Paneni F., Costantino S., Cosentino F. Role of oxidative stress in endothelial insulin resistance. World J. Diabetes 2015, 6:326-332.
119. Belia S., Santilli F., Beccafico S., De Feudis L., Morabito C., Davi G., et al. Oxidative-induced membrane damage in diabetes lymphocytes: effects on intracellular Ca(2+) homeostasis. Free Radic. Res. 2009, 43:138-148.
120. Funk S.D., Yurdagul A. Orr AW Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. Int. J. Vasc. Med. 2012, 569654. (2012).
121. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1032-1037.
122. Cosentino F., Eto M., De Paolis P., van der Loo B., Bachschmid M., Ullrich V., et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003, 107:1017-1023.
123. Du X., Edelstein D., Obici S., Higham N., Zou M.H., Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J. Clin. Invest. 2006, 116:1071-1080.
124. Pagnin E., Fadini G., de Toni R., Tiengo A., Calo L., Avogaro A. Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress. J. Clin. Endocrinol. Metab. 2005, 90:1130-1136.
125. Paneni F., Cosentino F. p66 Shc as the engine of vascular aging. Curr. Vasc. Pharmacol. 2012, 10:697-699.
126. Camici G.G., Schiavoni M., Francia P., Bachschmid M., Martin-Padura I., Hersberger M., et al. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc. Natl. Acad. Sci. 2007, 104:5217-5222.
127. Chen H.Z., Wan Y.Z., Liu D.P. Cross-talk between SIRT1 and p66Shc in vascular diseases. Trends Cardiovasc. Med. 2013, 23:237-241.
128. Tousoulis D., Papageorgiou N., Androulakis E., Siasos G., Latsios G., Tentolouris K., et al. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J. Am. Coll. Cardiol. 2013, 62:667-676.
129. Spranger J., Kroke A., Möhlig M., Hoffmann K., Bergmann M.M., Ristow M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
130. O'Connell T.M., Markunas C.A. DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes. Curr. Diabetes Rev. 2015.
131. Yara S., Lavoie J.C., Levy E. Oxidative stress and DNA methylation regulation in the metabolic syndrome. Epigenomics 2015, 7:283-300.
132. Chambers J.C., Loh M., Lehne B., Drong A., Kriebel J., Motta V., et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study. Lancet Diabet. Endocrinol. 2015, 3:526-534.
133. Gillberg L., Ling C. The potential use of DNA methylation biomarkers to identify risk and progression of type 2 diabetes. Front. Endocrinol. 2015, 6:43.
134. Nilsson E., Jansson P.A., Perfilyev A., Volkov P., Pedersen M., Svensson M.K., et al. Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes. Diabetes 2014, 63:2962-2976.
135. Zampetaki A., Kiechl S., Drozdov I., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 2010, 107:810-817.
136. Shantsila E., Kamphuisen P.W., Lip G.Y. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J. Thromb. Haemost. 2010, 8:2358-2368.
137. Tsimerman G., Roguin A., Bachar A., Melamed E., Brenner B., Aharon A. Involvement of microparticles in diabetic vascular complications. Thromb. Haemost. 2011, 106:310-321.
138. Chen Y., Feng B., Li X., Ni Y., Luo Y. Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes. J. Clin. Hypertens. (Greenwich) 2012, 14:455-460.
139. Bernard S., Loffroy R., Sérusclat A., Boussel L., Bonnefoy E., Thévenon C., et al. Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis 2009, 203:429-435.
140. May J.M., Harrison F.E. Role of vitamin C in the function of the vascular endothelium. Antioxid. Redox Signal. 2013, 19:2068-2083.
141. Bozaykut P., Karademir B., Yazgan B., Sozen E., Siow R.C., Mann G.E., et al. Effects of vitamin E on peroxisome proliferator-activated receptor and nuclear factor-erythroid related factor 2 in hypercholesterolemia-induced atherosclerosis. Free Radic. Biol. Med. 2014, 70:174-181.
142. Chiarelli F., Santilli F., Sabatino G., Blasetti A., Tumini S., Cipollone F., et al. Effects of vitamin E supplementation on intracellular antioxidant enzyme production in adolescents with type 1 diabetes and early microangiopathy. Pediatr. Res. 2004, 56:720-725.
143. Siti H.N., Kamisah Y., Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vasc. Pharmacol. 2015.
144. Kris-Etherton P.M., Lichtenstein A.H., Howard B.V., Steinberg D., Witztum J.L. Nutrition Committee of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004, 110:637-641.
145. Buijsse B., Feskens E.J.M., Kwape L., Kok F.J., Kromhout D. Both a- and b carotene, but not tocopherols and vitamin C, are inversely related to 15-year cardiovascular mortality in Dutch elderly men. J. Nutr. 2008, 138:344-350.
146. Mahajan A.S., Babbar R., Kansal N., Agarwal S.K., Ray P.C. Antihypertensive and antioxidant action of amlodipine and vitamin C in patients of essential hypertension. J. Clin. Biochem. Nutr. 2007, 40:141-147.
147. Rodrigo R., Prat H., Passalacqua W., Araya J., Bächler J.P. Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension. Clin. Sci. 2008, 114:625-634.
148. Vivekananthan D.P., Penn M.S., Sapp S.K., Hsu A., Topol E.J. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet 2003, 361:2017-2023.
149. Eidelman R.S., Hollar D., Hebert P.R., Lamas G.A., Hennekens C.H. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch. Intern. Med. 2004, 164:1552-1556.
150. Cook N.R., Albert S.M., Gaziano J.M., Zaharris E., MacFadyen J., Danielson E., et al. A randomized factorial trial of vitamins C, E, and beta-carotene in the secondary prevention of cardiovascular events in women: results from the women's antioxidant cardiovascular study (WACS). Arch. Intern. Med. 2007, 167:1610-1618.
151. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142:37-46.
152. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007, 297:842-857.
153. Montezano A.C., Touyz R.M. Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research. Antioxid. Redox Signal. 2014, 20:164-182.
154. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362:1675-1685.
155. Meagher E.A., Barry O.P., Lawson J.A., Rokach J., FitzGerald G.A. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001, 285:1178-1182.
156. Block G., Jensen C.D., Morrow J.D., Holland N., Norkus E.P., Milne G.L., et al. The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic. Biol. Med. 2008, 45:377-384.
157. Roberts L.J., Oates J.A., Linton M.F., Fazio S., Meador B.P., Gross M.D., et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic. Biol. Med. 2007, 43:1388-1393.
158. Davì G., Santilli F., Patrono C. Nutraceuticals in diabetes and metabolic syndrome. Cardiovasc. Ther. 2010, 28:216-226.
159. Hansen A.S., Marckmann P., Dragsted L.O., Finné Nielsen I.L., Nielsen S.E., Grønbaek M. Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease. Eur. J. Clin. Nutr. 2005, 59:449-455.
160. Lippi G., Franchini M., Favaloro E.J., Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". Semin. Thromb. Hemost. 2010, 36:59-70.
161. Gresele P., Cerletti C., Guglielmini G., Pignatelli P., de Gaetano G., Violi F. Effects of resveratrol and other wine polyphenols on vascular function: an update. J. Nutr. Biochem. 2011, 22:201-211.
162. Scoditti E., Calabriso N., Massaro M., Pellegrino M., Storelli C., Martines G., et al. Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch. Biochem. Biophys. 2012, 527:81-89.
163. Botden I.P., Oeseburg H., Durik M., Leijten F.P., Van Vark-Van Der Zee L.C., Musterd-Bhaggoe U.M., et al. Red wine extract protects against oxidative-stress-induced endothelial senescence. Clin. Sci. 2012, 123:499-507.
164. Schrieks I.C., van den Berg R., Sierksma A., Beulens J.W., Vaes W.H., Hendriks H.F. Effect of red wine consumption on biomarkers of oxidative stress. Alcohol Alcohol. 2013, 48:153-159.
165. Daiber A., Münzel T. Characterization of the antioxidant properties of pentaerithrityl tetranitrate (PETN)-induction of the intrinsic antioxidative system heme oxygenase-1 (HO-1). Methods Mol. Biol. 2010, 594:311-326.
166. Munzel T., Gori T. Nebivolol: the somewhat-different betaadrenergic receptor blocker. J. Am. Coll. Cardiol. 2009, 54:1491-1499.
167. Fratta Pasini A., Garbin U., Nava M.C., Stranieri C., Davoli A., Sawamura T., et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J. Hypertens. 2005, 23:589-596.
168. Violi F., Carnevale R., Pastori D., Pignatelli P. Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. Trends Cardiovasc. Med. 2014, 24:142-148.
169. Bonnefont-Rousselot D., Raji B., Walrand S., Gardès-Albert M., Jore D., Legrand A., et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 2003, 52:586-589.
170. Formoso G., De Filippis E.A., Michetti N., Di Fulvio P., Pandolfi A., Bucciarelli T., et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab. Res. Rev. 2008, 24:231-237.
171. Ferrannini E. The target of metformin in type 2 diabetes. N. Engl. J. Med. 2014, 371:1547-1548.
172. Randriamboavonjy V., Mann W.A., Elgheznawy A., Popp R., Rogowski P., Dornauf I., et al. Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity. Thromb. Haemost. 2015, 114.
173. Vázquez-Medina J.P., Popovich I., Thorwald M.A., Viscarra J.A., Rodriguez R., Sonanez-Organis J.G., et al. Angiotensin receptor-mediated oxidative stress is associated with impaired cardiac redox signaling and mitochondrial function in insulin-resistant rats. Am. J. Physiol. Heart Circ. Physiol. 2013, 305:H599-H607.
174. Chiarelli F., Di Marzio D., Santilli F., Mohn A., Blasetti A., Cipollone F., et al. Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. Diabetes Care 2005, 28:1690-1697.
175. Drummond G.R., Selemidis S., Griendling K.K., Sobey C.G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 2011, 10:453-471.
176. ten Freyhaus H., Huntgeburth M., Wingler K., Schnitker J., Bäumer A.T., Vantler M., et al. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc. Res. 2006, 71:331-341.
177. Laleu B., Gaggini F., Orchard M., Fioraso-Cartier L., Cagnon L., Houngninou-Molango S., et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J. Med. Chem. 2010, 53:7715-7730.
178. Gianni D., Taulet N., Zhang H., DerMardirossian C., Kister J., Martinez L., et al. A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem. Biol. 2010, 5:981-993.
179. Stachowicz A., Olszanecki R., Suski M., Wiśniewska A., Totoń-Z˙urańska J., Madej J., et al. Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice. J. Am. Heart Assoc. 2014, 3.
180. Fu S.H., Zhang H.F., Yang Z.B., Li T.B., Liu B., Lou Z., et al. Alda-1 reduces cerebral ischemia/reperfusion injury in rat through clearance of reactive aldehydes. Naunyn Schmiedeberg's Arch. Pharmacol. 2014, 387:87-94.
181. Dare A.J., Bolton E.A., Pettigrew G.J., Bradley J.A., Saeb-Parsy K., Murphy M.P. Protection against renal ischemia-reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ. Redox Biology 2015, 5:163-168.
182. Harris T.A., Yamakuchi M., Ferlito M., Mendell J.T., Lowenstein C.J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1516-1521.
183. Asgeirsdóttir S.A., van Solingen C., Kurniati N.F., Zwiers P.J., Heeringa P., van Meurs M., et al. MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation. Am. J. Physiol. Ren. Physiol. 2012, 302:F1630-F1639.
184. van Solingen C., de Boer H.C., Bijkerk R., Monge M., van Oeveren-Rietdijk A.M., Seghers L., et al. MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1(+)/Lin(-) progenitor cells in ischaemia. Cardiovasc. Res. 2011, 92:449-455.
185. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15:261-271.
186. Mondadori Dos Santos A., Metzinger L., Haddad O., M'baya-Moutoula E., Taïbi F., Charnaux N., et al. MiR-126 is involved in vascular remodeling under laminar shear stress. Biomed. Res. Int. 2015, 2015:497280.
187. Zampetaki A., Dudek K., Mayr M. Oxidative stress in atherosclerosis: the role of microRNAs in arterial remodeling. Free Radic. Biol. Med. 2013, 64:69-77.
188. Santilli F., Guagnano M.T., Vazzana N., La Barba S., Davi G. Oxidative stress drivers and modulators in obesity and cardiovascular disease: from biomarkers to therapeutic approach. Curr. Med. Chem. 2015, 22:582-595.
189. Sun X., Belkin N., Feinberg M.W. Endothelial microRNAs and atherosclerosis. Curr. Atheroscler. Rep. 2013, 15:372.
190. Watson J.D. Type 2 diabetes as a redox disease. Lancet 2014, 383:841-843.
191. Giorgio M. Oxidative stress and the unfulfilled promises of antioxidant agents. E cancer med. sci. 2015, 9:556.
192. Gupta S.C., Hevia D., Patchva S., Park B., Koh W., Aggarwal B.B. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. Redox Signal. 2012, 16:1295-1322.
193. Hitchler M.J., Domann F.E. Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome. Free Radic. Biol. Med. 2012, 53:2178-2187.
194. Sayin V.I., Ibrahim M.X., Larsson E., Nilsson J.A., Lindahl P., Bergo M.O. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 2014, 6. (221ra15).
195. Warburton D.E., Nicol C.W., Bredin S.S. Health benefits of physical activity: the evidence. Can. Med. Assoc. J. 2006, 174:801-809.